| 姓名 | 職稱 | 持有股份 | 代表法人 |
|---|---|---|---|
| Guo,Xu-Song | Chairman | 0.00% | |
| Huang,Zhi-Yuan | Director | 0.52% | |
| Cai,Pei-Shan | Director | 8.76% | SCHWEITZER BIOTECH COMPANY LTD. |
| Yang,Shi-Qin | Director | 0.50% | |
| Chen,Chun-Ye | Independent Director | 0.00% | |
| Liu,Jing-Hong | Independent Director | 0.00% | |
| Wu,Lie-Cheng | Independent Director | 0.00% |
Change Company Name to TAIWAN BIO THERAPEUTICS INC.
2024/07/03
Change Capital to 2,000,000,000
2024/07/03
Change Person in Charge to Guo,Xu-Song
2024/07/03
Change Company Name to TAIBAO BIOMEDICAL CO., LTD. (FORMER NAME: TAIBAO BIOMEDICAL CO., LTD.)
2022/10/19
Change Capital to 1,000,000,000
2021/04/06
Change Company Name to TAIWAN BIO THERAPEUTICS INC.
2017/07/14
Change Person in Charge to Huang,Zhi-Yuan
2017/07/14
Change Capital to 300,000,000
2016/12/15
下載完整報告查看完整數據
| 項目 | 2025 | 2024 | 2023 |
|---|---|---|---|
| Operating income | 11,445 | 27,724 | 85,470 |
| Operating cost | 2,933 | 12,709 | 9,111 |
| Profit (loss) of initial recognition of biological asset and agricultural products | - | - | - |
| Profit (loss) on changes in fair value less costs to sell of biological asset for current period | - | - | - |
| Operating gross profit (loss) | 8,512 | 15,015 | 76,359 |
| Unrealized profit (loss) on sales of goods | - | - | - |
| Realized profit (loss) on sales of goods | - | - | - |
| Operating gross profit (loss), net | 8,512 | 15,015 | 76,359 |
| Operating expenses | 85,527 | 156,179 | 290,957 |
| Other gain (loss), net | - | - | - |
| Operating profit (loss) | -77,015 | -141,164 | -214,598 |
| Non-operating income and expenses | 965 | 3,209 | -2,914 |
| Net profit (loss) before tax | -76,050 | -137,955 | -217,512 |
| Income tax expense (benefits) | 0 | 0 | 0 |
| Net profit (loss) of ongoing business for the current period | -76,050 | -137,955 | -217,512 |
| Profit (loss) of closed units | - | - | - |
| Profit (loss) of non-jointly controlled equity before merger | - | - | - |
| Net profit (loss) for the current period | -76,050 | -137,955 | -217,512 |
| Other comprehensive profit (loss), net | 1,080 | 4,151 | -13,398 |
| Comprehensive net profit and loss of non-jointly controlled equity before merger | - | - | - |
| Total comprehensive profit and loss for the current period | -74,970 | -133,804 | -230,910 |
| Net profit (loss) attributable to owners of parent company | -76,050 | -137,955 | -217,512 |
| Net profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
| Net profit (loss) attributable to non-controlling interests | 0 | 0 | 0 |
| Comprehensive profit (loss) attributable to owners of parent company | -74,970 | -133,804 | -230,910 |
| Comprehensive profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
| Comprehensive profit (loss) attributable to non-controlling interests | 0 | 0 | 0 |
| Basic earnings per share (yuan) | 0 | -2 | -3 |
| 項目 | 2025 | 2024 | 2023 |
|---|---|---|---|
| Net cash inflow (outflow) from operating activities | -57,793 | -93,461 | -166,546 |
| Net cash inflows (outflows) from investing activities | -25,888 | -106,107 | -119,227 |
| Net cash inflow (outflow) from financing activities | -5,725 | 389,918 | 290,432 |
| Effect of Exchange Rate Changes on Cash and Cash Equivalents | 119 | 194 | -2,412 |
| Increase (decrease) in cash and cash equivalents in the current period | -89,287 | 190,544 | 2,247 |
| Beginning balance of cash and cash equivalents | 677,694 | 248,139 | 245,892 |
| Ending balance of cash and cash equivalents | 588,407 | 438,683 | 248,139 |
| 項目 | 2025 | 2024 | 2023 |
|---|---|---|---|
| Current asset | 703,549 | 535,604 | 333,179 |
| Non-current asset | 710,754 | 673,075 | 608,582 |
| Total asset | 1,414,303 | 1,208,679 | 941,761 |
| Current liability | 69,558 | 62,760 | 61,617 |
| Non-current liability | 324,140 | 259,921 | 266,853 |
| Total liability | 393,698 | 322,681 | 328,470 |
| share capital | 846,050 | 743,450 | 621,359 |
| Equity - secruity token | - | - | - |
| capital reserve | 604,515 | 293,196 | 223,959 |
| retained earning | -431,298 | -141,401 | -218,629 |
| Other equity | 1,338 | -9,247 | -13,398 |
| Treasury stock | - | - | - |
| Total equity attributable to owners of parent company | 1,020,605 | 885,998 | 613,291 |
| Equity attributable to former owner of business combination under common control | - | - | - |
| Equity attributable to non-controlling interest before business merger under common control | - | - | - |
| Non-controlling interests | 0 | 0 | - |
| Total Equity | 1,020,605 | 885,998 | 613,291 |
| Share capital awaiting retirement (unit: share) | - | - | - |
| Issued shares of advance equity (unit: shares) | 122,500 | 86,250 | 81,600 |
| Treasury shares of the parent company held by the parent company and its subsidiaries (unit: share) | 0 | 0 | 0 |
| Net asset value per share | 12 | 11 | 9 |
